Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus

Journal of Nuclear Medicine

Volumn 50, Issue 11, 2009, Pages 1815-1819

  Nogová, Lucia ^a   Boellaard, Ronald ^b   Kobe, Carsten ^b   Hoetjes, Nikie ^b   Zander, Thomas ^a   Gross, Stefan Hubert ^c   Dimitrijevic, Sasa ^c   Pellas, Theodore ^c   Eschner, Wolfgang ^a   Schmidt, Katja ^c   Bangard, Christopher ^a   Hayes, Wendy ^d   Thomas, Roman K ^a,e,f   Dietlein, Markus ^a   Giaccone, Giuseppe ^b   Hoekstra, Otto S ^b   Lammertsma, Adriaan A ^b   Wolf, Jürgen ^a,e  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e UNIVERSITY OF COLOGNE   (Germany)

^f CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

Author keywords

18F FDG; Everolimus; Lung cancer; Positron emission tomography

Indexed keywords

EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GLUCOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; BODY SURFACE; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; LUNG TUMOR; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PILOT STUDY; SCINTISCANNING; TIME; TRANSPORT AT THE CELLULAR LEVEL;

AGED; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 70350719369     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.065367     Document Type: Article

References (10)

1. National Cancer Institute. FDA Approval for Everolimus. Available at: http://www. cancer.gov/cancertopics/druginfo/fda-everolimus. Accessed September 16, 2009.
2. Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol. June 23, 2009 [Epub ahead of print].
3. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594-601. (Pubitemid 38796850)
4. Papadimitrakopoulou V, Soria JC, Douillard JY, et al. A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I) [abstract]. J Clin Oncol. 2007; 25(June 20 suppl):7589.
5. Westerterp M, Pruim J, Oyen W, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging. 2007;34:392-404. (Pubitemid 46295349)
6. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
7. Boellaard RHO, Lammertsma AA. Software tools for standardized analysis of FDG whole body studies in multi-center trials [abstract]. J Nucl Med. 2008;49(suppl):159P.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
9. Ma WW, Jacene H, Song D, et al. [18]Fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009;27:2697-2704.
10. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83-95.